title: Administration of secretin for autism alters dopamine metabolism in the central nervous system.
abstract: We evaluated the clinical effects of intravenously administered secretin in 12 children with autism (age range: 4-6 years, median age: 9 years, boy:girl=8:4). In addition, we investigated the association between improvement in symptoms and changes in the cerebrospinal fluid (CSF) homovanillic acid (HVA),5-hydroxyindole-3-acetic acid (5-HIAA), and 6R-5,6,7,8-tetrahydro-L-biopterin (BH(4)) levels after administration. After administration of secretin, the Autism Diagnostic Interview-Revised (ADI-R) score improved in 7 of the 12 children. However, the score deteriorated in 2 of the 12 children (in the item of 'restricted and repetitive, stereotyped interests and behaviors'). The HVA and BH(4) levels in CSF were increased in all children with improvement in the ADI-R score. In contrast, no patient without the elevation of the BH(4) level showed improvement in the score. These findings suggest that secretin activated metabolic turnover of dopamine in the central nervous system via BH(4), improving symptoms.
authors.affiliation: Department of Pediatrics, School of Medicine, University of Tokushima, 3-18-15, Kuramoto-cho, Tokushima-shi, Tokushima 770-8503, Japan. yoshihiro1973@me.pikara.ne.jp
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Toda
authors.forename: Kenji
authors.initials: K
authors.lastname: Mori
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Hashimoto
authors.forename: Masahito
authors.initials: M
authors.lastname: Miyazaki
authors.forename: Satoshi
authors.initials: S
authors.lastname: Nozaki
authors.forename: Yasuyoshi
authors.initials: Y
authors.lastname: Watanabe
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Kuroda
authors.forename: Shoji
authors.initials: S
authors.lastname: Kagami
mesh_terms: D001321:Autistic Disorder / Q000134:cerebrospinal fluid / Q000188:drug therapy*; D001708:Biopterins / Q000031:analogs & derivatives / Q000134:cerebrospinal fluid; D002490:Central Nervous System / Q000187:drug effects*; D002648:Child; D002675:Child, Preschool; D004298:Dopamine / Q000134:cerebrospinal fluid*; D005260:Female; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid; D006728:Hormones / Q000008:administration & dosage*; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid; D008297:Male; D011569:Psychiatric Status Rating Scales; D012633:Secretin / Q000008:administration & dosage*; D013997:Time Factors
chemical_list: D006728:Hormones; D012633:Secretin; D001708:Biopterins; D006897:Hydroxyindoleacetic Acid; C003402:sapropterin; D004298:Dopamine; D006719:Homovanillic Acid